, Tracking Stock Market Picks
Enter Symbol:
Rating: REGN
Neutral $565

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) downgraded to Neutral with price target $565 by Chardan Capital Markets

Monday,  Aug 31, 2015  8:25 AM ET by Lynn Gilbert

Chardan Capital Markets downgraded Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Neutral with price target
$565. Previously, Chardan Capital Markets rated Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) to Buy with price target $560 on 03/20/2015, when the stock price was valued at $491.85.

Regeneron Pharmaceuticals Inc. is a biopharmaceutical company that discovers, develops, and intends to commercialize therapeutic drugs for thetreatment of serious medical conditions. Regeneron's platform technologies include Targeted GenomicsTM, FunctionomicsTM, and Designer Protein TherapeuticsTM. Regeneron has drugs in clinical and preclinical development for the potential treatment of obesity, rheumatoid arthritis, cancer, allergies, asthma, amyotrophic lateral sclerosis, constipating conditions, ischemia, and other diseases and disorders. (PRESS RELEASE)

Chardan Capital Markets

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy